Question

Patients experiencing peripheral neuropathy while using bortezomib can lessen the neuropathy
by dosing twice weekly instead of once weekly
by dosing once weekly instead of twice weekly
by using the intravenous formulation instead of the subcutaneous formulation

Answer 1

Correct answer: by dosing once weekly instead of twice weekly.

Explanation: peripheral neuropathy with bortezomib is reduced by less frequent dosing (once weekly vs twice weekly). Also, subcutaneous administration causes less neuropathy than intravenous administration — so switching to SC (not IV) and/or reducing dose or frequency are common strategies. Supportive measures (dose hold/reduction, duloxetine for neuropathic pain, gabapentin/pregabalin, symptomatic care) are also used.